Federal Register #2026-14347

NCI Seeks Partners for Licensing and Co-Development of Cell Therapy Technologies

The National Cancer Institute (NCI), part of the National Institutes of Health, is seeking industry partners for licensing and research co-development of two innovative adoptive cell therapy technologies. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Technology Transfer Center - Technologies Offered: - T cell receptor (TCR)-engineered T cells with murine-human hybrid receptors - Part number: E10120240 - Enables GMP production of personalized T cell therapy products targeting tumor-specific mutations - Designed for metastatic cancers, with enhanced persistence and performance - Papilloma Infiltrating Lymphocyte (PIL) Cell Therapy Products - Part number: E1432024 - Method for manufacturing PIL cell therapy products for chronic HPV 6 or 11 infections - Targets conditions such as recurrent respiratory papillomatosis and anogenital condyloma - Unique/Notable Requirements: - Opportunity is for licensing and/or research collaboration, not for direct product or service procurement - No specific OEMs or commercial vendors are named; NCI is the developer and licensor - Partners should have expertise in cell therapy, immunology, and clinical development - Technologies are protected by international patents - Quantities and purchase orders are not specified, as this is a technology transfer and collaboration opportunity

Description

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the development of papilloma-infiltrating lymphocytes (PIL) as a treatment for patients with chronic human papillomavirus (HPV) 6 or 11 infections. This novel adoptive cell therapy targets conditions such as recurrent respiratory papillomatosis (RRP) and anogenital condyloma caused by chronic HPV infection. The therapy involves isolating and expanding HPV-specific T cells from papilloma tissue to eliminate papillomatous growths. The NCI is looking for industry partners to support clinical development and commercialization of this approach, which addresses a significant unmet medical need with no approved systemic therapies currently available.

View original listing